HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.
Portrait of Denis Fitzgerald, MD

Denis Fitzgerald, MD, Board Chairperson

Board Certifications: Hematology, Internal Medicine and Medical Oncology

Languages: English

Locations: Little Silver, NJ

Call Little Silver, NJ: (732) 530-8666

Denis Fitzgerald, MD, has over 30 years of experience serving Little Silver, New Jersey, and the Monmouth County region. He is the current Board Chairperson and a member of the governance committee at Regional Cancer Care Associates (RCCA), one of the largest cancer care specialist networks in the nation. He delivers exceptional patient care and has earned multiple awards for his service. Schedule an appointment with Dr. Fitzgerald today.

As a community oncologist, Dr. Fitzgerald treats patients with many types of cancer. However, he has extensive experience with the following:

He is also knowledgeable in diagnosing and treating many types of benign blood disorders, including anemia, deep venous thrombosis, and pulmonary embolism, along with blood malignancies like leukemias and myelodysplasia.

Dr. Fitzgerald’s office administers a variety of outpatient treatments. Patients may receive chemotherapy and immunotherapy for cancer. He also provides intravenous medications for rheumatological diseases, colitis, and multiple sclerosis.

Academic Appointments and Achievements

Dr. Fitzgerald has served Monmouth County for over 30 years. During this time, he has delivered an exceptional level of care that has been acknowledged with numerous awards. Dr. Fitzgerald’s accolades include the following publications:

  • Jersey’s Best Magazine Top Doctor: 2010-2023
  • Jersey’s Best Magazine Top Doctor for Women’s Health: 2010-2018; 2021-2024
  • Jersey’s Best Magazine Top Doctor for Cancer: 2012-2019; 2021-2023
  • New York Magazine Top Doctor: 2021-2024
  • Top Doctors: New York Metro Area (book series): 5th through 18th editions
  • Top Doctors: New York Metro Area (digital guide): 2016-2022

Dr. Fitzgerald also maintains membership with multiple medical organizations, including:

These organizations are committed to improving cancer care across the state and nation. This goal is accomplished in collaboration between oncologists, researchers, and other medical professionals. Dr. Fitzgerald’s memberships help him stay current with the latest discoveries and guidelines. They also give him the opportunity to work alongside other experts in his field.

Education

  • Medical school: State University of New York, Downstate Medical Center College of Medicine, 1978
  • Residency: St. Vincent’s Hospital and Medical Center, Internal Medicine 1981; Chief Residency, Internal Medicine, 1982
  • Fellowship: University of Rochester Medical Center, Hematology/Medical Oncology, 1985
  • Board certifications: Internal Medicine, Hematology, and Oncology

About Denis Fitzgerald, MD

Dr. Fitzgerald was initially attracted to the field of hematology. He enjoyed the opportunity to diagnose patients through laboratory studies. This scientific interest led him to medical oncology, a field that is constantly evolving with new discoveries.

These innovations make now an exciting time to work in oncology. Medical advances have led to the invention of multiple new therapies, including immunotherapy, CAR-T therapy, oral targeted therapy, and others. These therapies can treat life-threatening diagnoses with extraordinary results. Some patients are cured entirely, while others can manage their conditions for an extended time with fewer side effects and a higher quality of life.

“When I began my career, I realized there would be many advances in the fields of oncology and hematology,” says Dr. Fitzgerald. “We have the ability to treat diseases now with some extraordinary therapies, which has been most rewarding.”

With so many options now on the table, determining the most appropriate treatment plan requires expertise. “When seeing a new patient,” says Dr. Fitzgerald, “I usually provide a written explanation of what they have and what treatments are possible.” He explains the diagnosis, options, and prognosis in lay terms to help patients understand as well as possible. This, in combination with Dr. Fitzgerald’s guidance, helps them make informed decisions about their care.

“Everyone’s cancer is different,” he adds, “and approach to treatment can vary greatly.” Regarding each individual as unique is a central part of Dr. Fitzgerald’s approach to care. Not only do patients struggle with unique diagnoses, but they also face concurrent conditions and other life factors. Oncologists must treat the whole patient, not just their cancer. This requires working closely with patients to understand their context.

“My philosophy of care is to engage with patients and families in a cooperative environment,” explains Dr. Fitzgerald. “I learn what their expectations and desires are, in order to guide them with appropriate counsel… and there are times when empathetic listening offers the most comfort.”

When Dr. Fitzgerald gets so involved with his patients, watching them improve is highly rewarding. He derives an immense sense of gratification when receiving letters of thanks from patients who he has helped through a difficult time. “Our entire office staff, including physicians, nurses, and nurse practitioners, shares this feeling,” he adds.

Locations

Dr. Fitzgerald treats patients at the RCCA office in Little Silver, NJ.

180 White Rd
Ste. 101
Little Silver NJ 07739

Hospital Affiliations

He is also the Medical Director of the cancer center at Riverview Medical Center and a Cancer Committee member with the Hackensack Meridian Health network.

We are here for you

For more information or to schedule an appointment, call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.